5-chloro-3-(2-fluorobenzylidene)indolin-2-one | 387343-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-chloro-3-(2-fluorobenzylidene)indolin-2-one
• 英文别名: BSc3921；5-chloro-3-[(2-fluorophenyl)methylidene]-1H-indol-2-one
• CAS: 387343-46-6
• 化学式: C₁₅H₉ClFNO
• mdl: MFCD05031486
• 分子量: 273.694
• InChiKey: ZFWPEZWERSHDNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-氯氧化吲哚 、 2-氟苯甲醛 在 哌啶 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以37%的产率得到5-chloro-3-(2-fluorobenzylidene)indolin-2-one
  参考文献：
  名称：

  Inhibition of γ-secretase by the CK1 inhibitor IC261 does not depend on CK1δ

  摘要：

  CK1 and gamma-secretase are interesting targets for therapeutic intervention in the treatment of cancer and Alzheimer's disease. The CK1 inhibitor IC261 was reported to inhibit gamma-secretase activity. The question is: Does CK1 inhibition directly influence gamma-secretase activity? Therefore we analyzed the SAR of 15 analogues and their impact on gamma-secretase activity. The most active compounds were investigated on CK1 delta activity. These findings exclude a direct influence of CK1 delta on gamma-secretase, because any change in the substitution pattern of IC261 diminished CK1 inhibition, whereas gamma-secretase inhibition is still exerted by several analogues. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.110

文献信息

• BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE
  申请人：GO Mei Lin

  公开号：US20130035364A1

  公开（公告）日：2013-02-07

  Compounds of general formula I: wherein R 1a , R 1b , R 2 , R 3a , R 3b and X are as defined herein are tyrosine kinase inhibitors and are useful for the treatment of various diseases and conditions, for example cancer.

  通式I的化合物： 其中 R 1a ，R 1b ，R 2 ，R 3a ，R 3b 和X如本文所定义的那样是酪氨酸激酶抑制剂，对于治疗各种疾病和病况，例如癌症，是有用的。
• US8877946B2
  申请人：——

  公开号：US8877946B2

  公开（公告）日：2014-11-04
• Inhibition of γ-secretase by the CK1 inhibitor IC261 does not depend on CK1δ
  作者：Nicole Höttecke、Miriam Liebeck、Karlheinz Baumann、Robert Schubenel、Edith Winkler、Harald Steiner、Boris Schmidt

  DOI：10.1016/j.bmcl.2010.02.110

  日期：2010.5

  CK1 and gamma-secretase are interesting targets for therapeutic intervention in the treatment of cancer and Alzheimer's disease. The CK1 inhibitor IC261 was reported to inhibit gamma-secretase activity. The question is: Does CK1 inhibition directly influence gamma-secretase activity? Therefore we analyzed the SAR of 15 analogues and their impact on gamma-secretase activity. The most active compounds were investigated on CK1 delta activity. These findings exclude a direct influence of CK1 delta on gamma-secretase, because any change in the substitution pattern of IC261 diminished CK1 inhibition, whereas gamma-secretase inhibition is still exerted by several analogues. (C) 2010 Elsevier Ltd. All rights reserved.